Clinical Study on Different Doses of Qingfei Dayuan Granule in The Treatment of Influenza

Hubei Provincial Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•To participate in the study, all of the following criteria are met:
•(1) It meets the clinical diagnostic criteria for influenza;
•(2) In line with the traditional Chinese medicine standard of heat toxicity to the lung;
•(3) Aged 18-70 years;
•(4) Fever duration <= 48h; Axillary temperature is 37.3 degrees or higher;
•(5) Rapid antigen detection of influenza virus in throat swab was positive;
•Informed consent process in accordance with the regulations, signed the informed consent.

•You may not participate in the study if you:
•(1) Severe or critical cases of influenza, or diagnosed as Covid-19, pharyngeal conjunctive membrane fever, herpetic pharyngitis, suppurative tonsillitis, etc.;
•(2) Complications of influenza such as sinusitis, otitis media and pneumonia;
•(3) The anti-influenza drugs included in the Influenza Diagnosis and Treatment Plan (2020 Edition) have been used within 48 hours before the visit;
•(4) Systematically receiving steroid therapy or other immunosuppressive therapy;
•(5) Have a history of epilepsy or febrile convulsions;
•(6) Patients with severe malnutrition, rickets and complicated with heart, brain, liver, kidney and hematopoietic system serious primary diseases;
•(7) Pregnant or lactating women with allergies, allergies to multiple drugs, or allergies to known ingredients of the study drug;
•According to the researchers' judgment, there are other lesions or conditions that reduce the possibility of inclusion or complicate inclusion, such as unstable living environment, inconvenient transportation and other conditions that are easy to cause loss of follow-up.

发起方